Zobrazeno 1 - 10
of 127
pro vyhledávání: '"B. Bonvoisin"'
Autor:
B. Bonvoisin, A. Brandao, M. Hatzenbichler, M. Scheerer, Zoltan Simon, Sascha Senck, T. Ghidini
Publikováno v:
CEAS Space Journal. 15:27-35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d72a03334b3c33e1047fe8a426baba6
https://doi.org/10.1007/s12567-022-00435-2
https://doi.org/10.1007/s12567-022-00435-2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
T. Lips, G. Sinnema, B. Bonvoisin, B. Fritsche, A. Gülhan, R. Kanzler, Tiago Soares, T. Schleutker
The concern about the on-ground risk caused by spacecraft fragments surviving atmospheric re-entry has significantly grown during the past decade, resulting in numerous activities of the space community like re-entry simulation tool development, impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2778c96bcf9449f727aaa1d97cc24b
https://elib.dlr.de/121514/
https://elib.dlr.de/121514/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marc K. Drezner, Peter L. Lakatos, J-Y Reginster, Dieter Felsenberg, Paul D. Miller, Claus Christiansen, Cyrus Cooper, Jan J. Stepan, Maria Greenwald, B. Bonvoisin, Pierre D. Delmas, N. Mairon, Lucy Rowell, Ronald Emkey, Silvano Adami, Stuart L. Silverman
Publikováno v:
Annals of the Rheumatic Diseases. 65:654-661
BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adc6dd642229daa4f0f819c36ab45c04
https://doi.org/10.1136/ard.2005.044958
https://doi.org/10.1136/ard.2005.044958
Autor:
B. Bonvoisin, Pierre D. Delmas, David L. Kendler, N. Mairon, Robert R. Recker, M. A. Bolognese, Dieter Felsenberg, Michael R. McClung, J. A. Stakkestad, Paul D. Miller, Jean-Yves Reginster, Cyrus Cooper, Marjorie M. Luckey, Liviu Macovei, E. Michael Lewiecki, C. Hughes
Publikováno v:
Journal of Bone and Mineral Research. 20:1315-1322
Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ab7977a0745adeaa1a78e340f0becf8
https://doi.org/10.1359/jbmr.050313
https://doi.org/10.1359/jbmr.050313
Autor:
P Mahoney, Robert R. Recker, R. C. Schimmer, Robert S. Weinstein, Charles H. Chesnut, C. Hughes, Pierre J. Meunier, B. Bonvoisin
Publikováno v:
Osteoporosis International. 15:231-237
The bisphosphonate ibandronate, administered either daily or intermittently with an extended between-dose interval of >2 months, has been shown to reduce significantly the incidence of vertebral fractures, to increase bone mineral density and to redu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b9dfbcb68fc4641053256e985b7f16d
https://doi.org/10.1007/s00198-003-1530-0
https://doi.org/10.1007/s00198-003-1530-0
Autor:
Lucy Rowell, B. Bonvoisin, Robert R. Recker, Edward Czerwiński, Louis George Ste-Marie, Daiva Masanauskaite, Bente L. Langdahl, Dieter Felsenberg
Publikováno v:
Recker, R R, Ste-Marie, L-G, Langdahl, B, Czerwinski, E, Bonvoisin, B, Masanauskaite, D, Rowell, L & Felsenberg, D 2010, ' Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study ', Bone, vol. 46, no. 3, pp. 660-5 . https://doi.org/10.1016/j.bone.2009.11.004
Udgivelsesdato: 2010-Mar In the Dosing IntraVenous Administration (DIVA) study, IV ibandronate injections (15-30 s duration) provided significantly greater gains in bone mineral density than daily oral ibandronate (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223d307879a3193c389d73f2a19279d7
https://pubmed.ncbi.nlm.nih.gov/19909829
https://pubmed.ncbi.nlm.nih.gov/19909829
Autor:
Cyrus Cooper, M. A. Bolognese, Michael R. McClung, Jean-Yves Reginster, Robert R. Recker, B. Bonvoisin, David L. Kendler, J. A. Stakkestad, Silvano Adami, Paul D. Miller, Roberto Civitelli, Dieter Felsenberg, Etienne Dumont, Pierre D. Delmas
Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has promp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f488d9f60b4ccfe80c680fdf9dc5b0
http://hdl.handle.net/11562/306453
http://hdl.handle.net/11562/306453